Table 7.
Gastric mucosal changes at EGD according the administration of anticoagulants and the rate of H. pylori detection.
| Altered gastric mucosa | H. pylori | Patients receiving anticoagulants, | Patients not receiving anticoagulants, | Comparison group, | P; OR (95%CI) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| n = 49 | n = 36 | n = 12 | |||||||||
| Antral gastritis, n (%) |
(+) | 40 (88.9) | 45 (91.8) | 16 (72.7) | 22 (61.1) | 3 (60.0) | 5 (41.7) | P 1 = 0.0004; OR = 15.75 (95% CI 3.39-73.26) | P2 = 0.14; OR = 5.33 (95% CI 0.71-40.06) | P 3 = 0.00076; OR = 7.16, (95% CI 2.11-24.31) | P4 = 0.09; OR = 3 (95% CI 0.80-11.24) |
| (-) | 5 (11.1) | 6 (27.3) | 2 (40.0) | ||||||||
|
| |||||||||||
| Pangastritis, n (%) |
(+) | 2 (100.0) | 2 (4.1) | 5 (100.0) | 5 (13.9) | 2 (100.0) | 2 (16.7) | P1 = 0.17; OR = 0.21 (95% CI 0.03-1.70) | P2 = 1 | P3 = 0.11; OR = 0.26 (95% CI 0.05-1.45) | P4 = 1 |
| (-) | 0 | 0 | 0 | ||||||||
|
| |||||||||||
| Gastric mucosal erosion, n (%) |
(+) | 10 (90.9) | 11 (22.4) | 8 (80.0) | 10 (27.8) | 2 (100.0) | 2 (16.7) | P1 = 0.50; OR = 1.45 (95% CI 0.28-7.61) | P2 = 0.85; OR = 0 (95% CI 0-NaN) | P3 = 0.38; OR = 0.75 (95% CI 0.28-2.03) | P4 = 0.46; OR = 2.5 (95% CI 0.19-32.80) |
| (-) | 1 (9.1) | 2 (20.0) | 0 | ||||||||
|
| |||||||||||
| Gastric mucosal hemorrhage, n (%) |
(+) | 4 (100.0) | 4 (8.2) | 2 (66.7) | 3 (8.3) | 1 (100.0) | 1 (8.3) | P1 = 0.68; OR = 0.98 (95% CI 0.10-9.64) | P2 = 1 | P3 = 0.64; OR = 0.98 (95% CI 0.20-4.67) | P4 = 0.43; OR = Infinity (95% CI NaN-Infinity) |
| (-) | 0 | 1 (33.3) | 0 | ||||||||
|
| |||||||||||
| Intact gastric mucosa, n (%) |
(+) | 2 (100.0) | 2 (4.1) | 4 (66.7) | 6 (16.7) | 2 (50.0) | 4 (33.3) | P 1 = 0.011; OR = 11.75; (95% CI 1.84-75.15) | P2 = 0.4; OR = Infinity (95% CI NaN-Infinity) | P3 = 0.057; OR = 0.21 (95% CI 0.04-1.12) | P4 = 0.54; OR = Infinity (95% CI NaN-Infinity) |
| (-) | 0 | 2 (33.3) | 2 (50.0) | ||||||||
Notes: The percentage of patients with appropriate GM changes in the anticoagulant, non-anticoagulant, and comparison groups was calculated from the total number of patients in the corresponding group.
The percentage of H. pylori-positive patients was calculated from the number of those with appropriate GM changes in the anticoagulant, non-anticoagulant, and comparison groups.
Р1: comparison of the number of patients with and without appropriate GM changes in the comparison and anticoagulant groups.
Р2: comparison of the number of H. pylori-positive and H. pylori-negative patients with an appropriate GM change in the comparison and anticoagulant groups.
Р3: comparison of the number of patients with and without appropriate GM changes in the anticoagulant and non-anticoagulant groups.
Р4: comparison of the number of H. pylori-positive and H. pylori-negative patients with an appropriate GM change in the anticoagulant and non-anticoagulant groups.